Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets - A Focus on the JAK-STAT Pathway

Pain Research and Management

Volumn 2018, Issue , 2018, Pages

  Salaffi, Fausto ^a   Giacobazzi, Giovanni ^b   Di Carlo, Marco ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; JANUS KINASE; JANUS KINASE INHIBITOR; STAT PROTEIN;

ANALGESIA; ARTHRALGIA; CHRONIC PAIN; DISEASE ASSESSMENT; HUMAN; JAK-STAT SIGNALING; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OBESITY; PAIN MEASUREMENT; PATHOGENESIS; PHARMACEUTICAL CARE; PSYCHOLOGICAL ASPECT; REVIEW; RHEUMATOID ARTHRITIS; ARTHRITIS; COMPLICATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ARTHRITIS; CHRONIC PAIN; HUMANS; JANUS KINASES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85042586716     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2018/8564215     Document Type: Review

References (174)

1. F. Atzeni, M. Cazzola, M. Benucci, M. Di Franco, F. Sala and P. Sarzi-Puttini, "Chronic widespread pain in the spectrum of rheumatological diseases, " Best Practice & Research Clinical Rheumatology, vol. 25, no. 2, pp. 165-171, 2011.
2. H. Merskey and N. Bogduk, Classi cation of Chronic Pain, IASP Publications, Seattle, WA, USA, 1994.
3. M. Busch-Dienstfertig and S. Gonzàlez-Rodrguez, "IL-4, JAK-STAT signaling, and pain, " JAK-STAT, vol. 2, no. 4, p. e27638, 2013.
4. B. Sa: eh-Garabedian, S. Poole, J. J. Haddad, C. A. Massaad, S. J. Jabbur, and N. E. Saade, ")e role of the sympathetic efferents in endotoxin-induced localized in2ammatory hyperalgesia and cytokine upregulation, " Neuropharmacology, vol. 42, no. 6, pp. 864-872, 2002.
5. J. Mika, "Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness, " Pharmacology Reports, vol. 60, no. 3, pp. 297-307, 2008.
6. J. M. Zhang and J. An, "Cytokines, in2ammation, and pain, " International Anesthesiology Clinics, vol. 45, no. 2, pp. 27-37, 2007.
7. R. J. Miller, H. Jung, S. K. Bhangoo, and F. A. White, "Cytokine and chemokine regulation of sensory neuron function, " Handbook of Experimental Pharmacology, vol. 194, pp. 417-449, 2009.
8. H. Obata, J. C. Eisenach, H. Hussain, T. Bynum, and M. Vincler, "Spinal glial activation contributes to postoperative mechanical hypersensitivity in the rat, " Journal of Pain, vol. 7, no. 11, pp. 816-822, 2006.
9. F. Q. Cunha and S. H. Ferreira, "Peripheral hyperalgesic cytokines, " Advances in Experimental Medicine and Biology, vol. 521, pp. 22-39, 2003.
10. R. Vallejo, D. M. Tilley, L. Vogel, and R. Benyamin, ")e role of glia and the immune system in the development and maintenance of neuropathic pain, " Pain Practice, vol. 10, no. 3, pp. 167-184, 2010.
11. C. M. B. de Oliveira, R. K. Sakata, A. M. Issy, L. R. Gerola, and R. Salomão, "Cytokines and pain, " Revista Brasileira de Anestesiologia, vol. 61, no. 2, pp. 255-259, 2011.
12. E. D. Milligan, K. R. Penzkover, R. G. Soderquist, and M. J. Mahoney, "Spinal interleukin-10 therapy to treat peripheral neuropathic pain, " Neuromodulation, vol. 15, no. 6, pp. 520-526, 2012.
13. C. Stein and C. Zollner, "Opioids and sensory nerves, " Handbook of Experimental Pharmacology, vol. 194, pp. 495-518, 2009.
14. H. L. Rittner, A. Brack, and C. Stein, ")e other side of the medal: how chemokines promote analgesia, " Neuroscience Letters, vol. 437, no. 3, pp. 203-208, 2008.
15. P. J. Cabot, L. Carter, C. Gaiddon et al., "Immune cellderived beta-endorphin. Production, release, and control of in2ammatory pain in rats, " Journal of Clinical Investigation, vol. 100, no. 1, pp. 142-148, 1997.
16. H. L. Rittner, H. Machelska, and C. Stein, "Leukocytes in the regulation of pain and analgesia, " Journal of Leukocyte Biology, vol. 78, no. 6, pp. 1215-1222, 2005.
17. A. Okifuji and B. Hare, ")e association between chronic pain and obesity, " Journal of Pain Research, vol. 8, pp. 399-408, 2015.
18. L. H. McCarthy, M. E. Bigal, M. Katz, C. Derby, and R. B. Lipton, "Chronic pain and obesity in elderly people: results from the Einstein aging study, " Journal of American Geriatrics Sociecty, vol. 57, no. 1, pp. 115-119, 2009.
19. G. Miscio, G. Guastamacchia, A. Brunani, L. Priano, S. Baudo, and A. Mauro, "Obesity and peripheral neuropathy risk: a dangerous liaison, " Journal of the Peripheral Nervous System, vol. 10, no. 4, pp. 354-358, 2005.
20. M. Bluher, M. Fasshauer, A. Tonjes, J. Kratzsch, M. R. Schon, and R. Paschke, "Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism, " Experimental and Clinical Endocrinology & Diabetes, vol. 113, no. 9, pp. 534-537, 2005.
21. U. N. Das, "Is obesity an in2ammatory condition, " Nutrition, vol. 17, no. 11-12, pp. 953-966, 2001.
22. A. Okifuji, G. W. Donaldson, L. Barck, and P. G. Fine, "Relationship between: bromyalgia and obesity in pain, function, mood, and sleep, " Journal of Pain, vol. 11, no. 12, pp. 1329-1337, 2010.
23. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., "Obesity is associated with macrophage accumulation in adipose tissue, " Journal of Clinical Investigations, vol. 112, no. 12, pp. 1796-1808, 2003.
24. K. E. Wellen and G. S. Hotamisligil, "Obesity-induced in-2ammatory changes in adipose tissue, " Journal of Clinical Investigations, vol. 112, no. 12, pp. 1785-1788, 2003.
25. D. B. Panagiotakos, C. Pitsavos, M. Yannakoulia, C. Chrysohoou, and C. Stefanadis, ")e implication of obesity and central fat on markers of chronic in2ammation: the ATTICA study, " Atherosclerosis, vol. 183, no. 2, pp. 308-315, 2005.
26. L. J. Sandell, "Obesity and osteoarthritis: is leptin the link?, " Arthritis and Rheumatism, vol. 60, no. 10, pp. 2858-2860, 2009.
27. N. Busso, A. So, V. Chobaz-Péclat et al., "Leptin signaling de: ciency impairs humoral and cellular immune responses and attenuates experimental arthritis, " Journal of Immunology, vol. 168, no. 2, pp. 875-882, 2002.
28. H. Forsblad d'Elia, R. Pullerits, H. Carlsten, and M. Bokarewa, "Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis, " Rheumatology, vol. 47, no. 7, pp. 1082-1087, 2008.
29. K. Sawicka and D. Krasowska, "Adipokines in connective tissue diseases, " Clinical and Experimental Rheumatology, vol. 34, no. 6, pp. 1101-1112, 2016.
30. K. W. Frommer, A. Schäer, C. Büchler et al., "Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?, " Annals of the Rheumatic Diseases, vol. 71, no. 10, pp. 1724-1732, 2012.
31. P. Dell'Albani, R. Santangelo, L. Torrisi, V. G. Nicoletti, and A. M. G. Stella, "Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS, " Neurochemical Research, vol. 28, no. 1, pp. 53-64, 2003.
32. S. Bauer, B. J. Kerr, and P. H. Patterson, ")e neuropoietic cytokine family in development, plasticity, disease and injury, " Nature Reviews Neuroscience, vol. 8, no. 3, pp. 221-232, 2007.
33. F. M. Bareyre, N. Garzorz, C. Lang, T. Misgeld, H. Buning, and M. Kerschensteiner, "In vivo imaging reveals a phasespeci: c role of STAT3 during central and peripheral nervous system axon regeneration, " Proceedings of the National Academy of Sciences, vol. 108, no. 15, pp. 6282-6287, 2011.
34. J. E. Herrmann, T. Imura, B. Song et al., "STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury, " Journal of Neuroscience, vol. 28, no. 28, pp. 7231-7243, 2008.
35. O. S. Kim, E. J. Park, E. H. Joe, and I. Jou, "JAK-STAT signalling mediates gangliosides-induced in2ammatory responses in brain microglial cells, " Journal of Biological Chemistry, vol. 277, no. 43, pp. 40594-40601, 2002.
36. H. Kiu and S. E. Nicholson, "Biology and signi: cance of the JAK/STAT signalling pathways, " Growth Factors, vol. 30, no. 2, pp. 88-106, 2012.
37. T. Mori, T. Miyamoto, H. Yoshida et al., "IL-1 and TNF-initiated IL-6-STAT3 pathway is critical in mediating in2ammatory cytokines and RANKL expression in in2ammatory arthritis, " International Immunology, vol. 23, no. 11, pp. 701-712, 2011.
38. E. Dominguez, A. Mauborgne, J. Mallet, M. Desclaux, and M. Pohl, "SOCS3-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroin2ammation and mechanical allodynia after peripheral nerve injury, " Journal of Neuroscience, vol. 30, no. 16, pp. 5754-5766, 2010.
39. M. A.)acker, A. K. Clark, F. Marchand, and S. B. McMahon, "Pathophysiology of peripheral neuropathic pain: immune cells and molecules, " Anesthesia & Analgesia, vol. 105, no. 3, pp. 838-847, 2007.
40. C. S. Sung, C. H. Cherng, Z. H. Wen et al., "Minocycline and 2uorocitrate suppress spinal nociceptive signaling in intrathecal IL-1-induced thermal hyperalgesic rats, " Glia, vol. 60, no. 12, pp. 2004-2017, 2012.
41. W. Kleibeuker, E. Gabay, A. Kavalaars et al., "IL-1 signaling is required for mechanical allodynia induced by nerve injury and for the ensuing reduction in spinal cord neuronal GRK2, " Brain, Behaviour and Immunity, vol. 22, no. 2, pp. 200-208, 2008.
42. G. K. Hershey, M. F. Friedrich, L. A. Esswein, M. L.)omas, and T. A. Chatila, ")e association of atopy with a gain-offunction mutation in the alpha subunit of the interleukin-4 receptor, " New England Journal of Medicine, vol. 337, no. 24, pp. 1720-1725, 1997.
43. M. Wills-Karp and F. D. Finkelman, "Untangling the complex web of IL-4-and IL-13-mediated signalling pathways, " Science Signaling, vol. 1, no. 51, p. pe55, 2008.
44. F. Q. Cunha, S. Poole, B. B. Lorenzetti, F. H. Veiga, and S. H. Ferreira, "Cytokine-mediated in2ammatory hyperalgesia limited by interleukin-4, " British Journal of Pharmacology, vol. 126, no. 1, pp. 45-50, 1999.
45. W. A. Verri Jr., T. M. Cunha, C. A. Parada, S. Poole, F. Q. Cunha, and S. H. Ferreira, "Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?, " Pharmacology & 5erapeutics, vol. 112, no. 1, pp. 116-138, 2006.
46. T. S. Huber, G. S. Gaines, M. B. Welborn III, J. J. Rosenberg, J. M. Seeger, and L. L. Moldawer, "Anticytokine therapies for acute in2ammation and the systemic in2ammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm, " Shock, vol. 13, no. 6, pp. 425-434, 2000.
47. R. Baron, A. Binder, and G. Wasner, "Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment, " 5e Lancet Neurology, vol. 9, no. 8, pp. 807-819, 2010.
48. M. Tsuda, Y. Kohro, T. Yano et al., "JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats, " Brain, vol. 134, no. 4, pp. 1127-1139, 2011.
49. J. Molet, A. Mauborgne, M. Diallo et al., "Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics, " Journal of Neurochemistry, vol. 136, no. 1, pp. 133-147, 2016.
50. C. Börner, M. Wöltje, V. Höllt, and J. Kraus, "STAT6 transcription factor binding sites with mismatches within the canonical 5-TTC.. GAA-3 motif involved in regulation of delta-and mu-opioid receptors, " Journal of Neurochemistry, vol. 91, no. 6, pp. 1493-1500, 2004.
51. J. Kraus, C. Börner, E. Giannini et al., "Regulation of muopioid receptor gene transcription by interleukin-4 and in2uence of an allelic variation within a STAT6 transcription factor binding site, " Journal of Biological Chemistry, vol. 276, no. 43, pp. 43901-43908, 2001.
52. M. Busch-Dienstfertig, D. Labuz, T. Wolfram, N. N. Vogel, and C. Stein, "JAK-STAT1/3-induced expression of signal sequenceencoding proopiomelanocortin mRNA in lymphocytes reduces in2ammatory pain in rats, " Molecular Pain, vol. 8, p. 83, 2012.
53. A. E. Panerai and P. Sacerdote, "Beta-endorphin in the immune system: a role at last?, " Immunology Today, vol. 18, no. 7, pp. 317-319, 1997.
54. C. Börner, S. Lanciotti, T. Koch, V. Höllt, and J. Kraus, " opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes, " Journal of Neuroimmunology, vol. 263, no. 1-2, pp. 35-42, 2013.
55. M. L. Vale, J. B. Marques, C. A. Moreira et al., "Antinociceptive effects of interleukin-4,-10, and-13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats, " Journal of Pharmacology and Experimental 5erapeutics, vol. 304, no. 1, pp. 102-108, 2003.
56. N. Ueyler, T. Topuzoglu, P. Schiesser, S. Hahnenkamp, and C. Sommer, "IL-4 de: ciency is associated with mechanical hypersensitivity in mice, " PLoS One, vol. 6, no. 12, article e28205, 2011.
57. J. F. Marcelletti, J. Ohara, and D. H. Katz, "Collagen-induced arthritis in mice. Relationship of collagen-speci: c and total IgE synthesis to disease, " Journal of Immunology, vol. 147, no. 12, pp. 4185-4191, 1991.
58. K. Shuai, "Regulation of cytokine signaling pathways by PIAS proteins, " Cell Research, vol. 16, pp. 196-202, 2006.
59. G. da Rocha Castelar Pinheiro, R. K. Khandker, R. Sato, A. Rose, and J. Piercy, "Impact of rheumatoid arthritis on quality of life, work productivity and resource utilisation: an observational, cross-sectional study in Brazil, " Clinical and Experimental Rheumatology, vol. 31, no. 3, pp. 334-340, 2013.
60. F. Atzeni, L. Boccassini, M. Di Franco et al., "Chronic widespread in spondyloarthritis, " Reumatismo, vol. 66, no. 1, pp. 28-32, 2014.
61. American College of Rheumatology Pain Management Task Force, "Report of the American College of Rheumatology Pain Management Task Force, " Arthritis Care & Research, vol. 62, no. 5, pp. 590-599, 2010.
62. N. Courvoisier, M. Dougados, A. Cantagrel et al., "Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study, " Arthritis Research & 5erapy, vol. 10, no. 5, p. R106, 2008.
63. S. Odegard, A. Finset, P. Mowinckel, T. K. Kvien, and T. Uhlig, "Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis, " Annals of the Rheumatic Disease, vol. 66, no. 9, pp. 1195-1201, 2007.
64. T. Sokka, A. Kankainen, and P. Hannonen, "Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores, " Arthritis and Rheumatism, vol. 43, no. 2, pp. 386-389, 2000.
65. P. Sarzi-Puttini, T. Fiorini, B. Panni, M. Turiel, M. Cazzola, and F. Atzeni, "Correlation of the score for subjective pain with physical disability, clinical, and radiographic scores in recent onset rheumatoid arthritis, " BMC Musculoskeletal Disorders, vol. 3, p. 18, 2002.
66. N. A. Khan, H. J. Spencer, E. Abda et al., "Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity, " Arthritis Care & Research, vol. 64, no. 2, pp. 206-214, 2012.
67. P. Studenic, H. Radner, J. S. Smolen, and D. Aletaha, "Discrepancies between patients and physicians in the perception of rheumatoid arthritis disease activity, " Arthritis and Rheumatism, vol. 64, no. 9, pp. 2814-2823, 2012.
68. Y. C. Lee, J. Cui, B. Lu et al., "Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study, " Arthritis Research & 5erapy, vol. 13, no. 3, p. R83, 2011.
69. P. Sarzi-Puttini, F. Sala M. Di Franco et al., "Pain in rheumatoid arthritis: a critical review, " Reumatismo, vol. 66, no. 1, pp. 18-27, 2014.
70. D. A. Walsh and D. F. McWilliams, "Pain in rheumatoid arthritis, " Current Pain Headache Reports, vol. 16, no. 6, pp. 509-517, 2012.
71. D. A. Walsh and D. F. McWilliams, "Mechanisms, impact and management of pain in rheumatoid arthritis, " Nature Reviews Rheumatology, vol. 10, no. 10, pp. 581-592, 2014.
72. V. I. Shubayev, K. Kato, and R. E. Myers, Translational Pain Research: from Mouse to Man, L. Kruger and A. R. Light, Eds., CRC Press, Boca Raton, FL, USA, 2010.
73. F. M. Brennan and I. B. McInnes, "Evidence that cytokines play a role in rheumatoid arthritis, " Journal of Clinical Investigation, vol. 118, no. 11, pp. 3537-3545, 2008.
74. M. Scuri, L. Samsell, and G. Piedimonte, ")e role of neurotrophins in in2ammation and allergy, " In8ammation & Allergy-Drug Targets, vol. 9, no. 3, pp. 173-180, 2010.
75. A. Antonelli, S. M. Ferrari, D. Giuggioli, E. Ferranini, C. Ferri, and P. Fallahi, "Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases, " Autoimmunity Reviews, vol. 13, no. 3, pp. 272-280, 2014.
76. R. A. Fava, N. J. Olsen, G. Spencer-Green et al., "Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial 2uids and rheumatoid synovial tissue, " Journal of Experimental Medicine, vol. 180, no. 1, pp. 341-346, 1994.
77. M. Meeus, S. Vervisch, L. S. De Clerck, G. Moorkens, G. Hans, and J. Nijs, "Central sensitization in patients with rheumatoid arthritis: a systematic literature review, " Seminars in Arthritis and Rheumatism, vol. 41, no. 4, pp. 556-567, 2012.
78. K. Toth, I. Barna, G. Nagy, K. Wellinger, G. Horvath, and T. Bender, "Synovial 2uid-endorphin level in avascular necrosis, rheumatoid arthritis, and osteoarthritis of the femoral head and knee. A controlled pilot study, " Clinical Rheumatology, vol. 30, no. 4, pp. 537-540, 2011.
79. C. W. Denko and C. J. Malemud, "Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases, " Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 24-34, 2005.
80. H. L. Wright, R. C. Bucknall, R. J. Moots, and S. W. Edwards, "Analysis of SF and plasma cytokines provides insights into the mechanisms of in2ammatory arthritis and may predict response to therapy, " Rheumatology, vol. 51, no. 3, pp. 451-459, 2012.
81. Z. Z. Xu, L. Zhang, T. Liu et al., "Resolvins RvE1 and RvD1 attenuate in2ammatory pain via central and peripheral actions, " Nature Medicine, vol. 16, no. 5, pp. 592-597, 2010.
82. M. Giera, A. Ioan-Facsinay, R. Toes et al., "Lipid and lipid mediator pro: ling of human synovial 2uid in rheumatoid arthritis patients by means of LC-MS/MS, " Biochimica et Biophysica Acta, vol. 1821, no. 11, pp. 1415-1424, 2012.
83. K. Phillips and D. J. Clauw, "Central pain mechanisms in the rheumatic diseases: future directions, " Arthritis and Rheumatism, vol. 65, no. 2, pp. 291-302, 2013.
84. L. C. Pollard, F. Ibrahim, E. H. Choy, and D. L. Scott, "Pain thresholds in rheumatoid arthritis: the effect of tender point counts and disease duration, " Journal of Rheumatology, vol. 39, no. 1, pp. 28-31, 2012.
85. T. Hummel, C. Schiessl, J. Wendler, and G. Kobal, "Peripheral and central nervous changes in patients with rheumatoid arthritis in response to repetitive painful stimulation, " International Journal of Psychophysiology, vol. 37, no. 2, pp. 177-183, 2000.
86. H. van Middendorp and A. W. M. Evers, ")e role of psychological factors in in2ammatory rheumatic diseases: from burden to tailored treatment, " Best Practice & Research Clinical Rheumatology, vol. 30, no. 5, pp. 932-945, 2016.
87. P. Schweinhardt, N. Kalk, K. Wartolowska, I. Chessell, P. Wordsworth, and I. Tracey, "Investigation into the neural correlates of emotional augmentation of clinical pain, " NeuroImage, vol. 40, no. 2, pp. 759-766, 2008.
88. A. K. Jones, Q. Liyi, V. V. Cunningham et al., "Endogenous opiate response to pain in rheumatoid arthritis and cortical and subcortical response to pain in normal volunteers using positron emission tomography, " International Journal of Clinical Pharmacology Research, vol. 11, no. 6, pp. 261-266, 1991.
89. R. R. Edwards, C. O. Bingham III, J. Bathon, and J. A. Haythornthwaite, "Catastrophizing and pain in arthritis,: bromyalgia, and other rheumatic diseases, " Arthritis and Rheumatism, vol. 55, no. 2, pp. 325-332, 2006.
90. D. L. Goldenberg, ")e interface of pain and mood disturbances in the rheumatic diseases, " Seminars in Arthritis Rheumatism, vol. 40, no. 1, pp. 15-31, 2010.
91. R. R. Edwards, C. Cahalan, G. Mensing, M. Smith, and J. A. Haythornthwaite, "Pain, catastrophizing, and depression in the rheumatic diseases, " Nature Reviews Rheumatology, vol. 7, no. 4, pp. 216-224, 2011.
92. F. Wolfe and K. Michaud, "Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity, " Arthritis and Rheumatism, vol. 61, no. 5, pp. 667-673, 2009.
93. J. Fi: eld, H. Tennen, S. Reisine, and J. McQuillan, "Depression and the long-term risk of pain, fatigue, and disability in patients with rheumatoid arthritis, " Arthritis and Rheumatism, vol. 41, no. 10, pp. 1851-1857, 1998.
94. I. Rupp, H. C. Boshuizen, H. J. Dinant, C. E. Jacobi, and G. A. van den Bos, "Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms, " Scandinavian Journal of Rheumatology, vol. 35, no. 3, pp. 175-181, 2006.
95. S. Urrows, G. Aeck, H. Tennen, and P. Higgins, "Unique clinical and psychological correlates of: bromyalgia tender points and joint tenderness in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 37, no. 10, pp. 1513-1520, 1994.
96. P. Dharmshaktu, V. Tayal, and B. S. Kalra, "E(cacy of antidepressants as analgesics: a review, " Journal of Clinical Pharmacology, vol. 52, no. 1, pp. 6-17, 2012.
97. A. J. Zautra, M. C. Davis, J. W. Reich et al., "Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression, " Journal of Consulting and Clinical Psychology, vol. 76, no. 3, pp. 408-421, 2008.
98. F. Wolfe, "Fibromyalgianess, " Arthritis and Rheumatism, vol. 61, no. 6, pp. 715-716, 2009.
99. F. Wolfe, D. J. Clauw, M. A. Fitzcharles et al., "Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modi: cation of the ACR preliminary diagnostic criteria for: bromyalgia, " Journal of Rheumatology, vol. 38, no. 6, pp. 1113-1122, 2011.
100. L. E. Kazis, R. F. Meenan, and J. J. Anderson, "Pain in the rheumatic diseases. Investigation of a key health status component, " Arthritis and Rheumatism, vol. 26, no. 8, pp. 1017-1022, 1983.
101. F. Sala P. Sarzi-Puttini, and F. Atzeni, "How to measure chronic pain: new concepts, " Best Practice & Research Clinical Rheumatology, vol. 29, no. 1, pp. 164-186, 2015.
102. F. Sala P. Sarzi-Puttini, A. Ciapetti, and F. Atzeni, "Clinimetric evaluations of patients with chronic widespread pain, " Best Practice & Research Clinical Rheumatology, vol. 25, no. 2, pp. 249-270, 2011.
103. F. Sala P. Sarzi-Puttini, A. Ciapetti, and F. Atzeni, "Assessment instruments for patients with: bromyalgia: properties, applications and interpretation, " Clinical and Experimental Rheumatology, vol. 27, no. 5, pp. S92-S105, 2009.
104. T. Sokka, "Assessment of pain in patients with rheumatic diseases, " in Pain Best Practice and Research Compendium, H. Breivik and M. Shipley, Eds., pp. 27-42, Elsevier, London, UK, 2007.
105. C. S. Burckhardt, ")e use of the McGill Pain Questionnaire in assessing arthritis pain, " Pain, vol. 19, no. 3, pp. 305-314, 1984.
106. R. Melzack, ")e short-form McGill pain questionnaire, " Pain, vol. 30, no. 2, pp. 191-197, 1987.
107. C. S. Cleeland and K. M. Ryan, "Pain assessment: global use of the brief pain inventory, " Annals Academy of Medicine Singapore, vol. 23, no. 2, pp. 129-138, 1994.
108. R. D. Kerns, D. C. Turk, and T. E. Rudy, ")e West Haven-Yale multidimensional pain inventory (WHYMPI), " Pain, vol. 23, no. 4, pp. 345-356, 1985.
109. D. L. Anderson, "Development of an instrument to measure pain in rheumatoid arthritis: rheumatoid arthritis pain scale (RAPS), " Arthritis and Rheumatism, vol. 45, no. 4, pp. 317-323, 2001.
110. S. Ahmed, T. Magan, M. Vargas, A. Harrison, and N. Sofat, "Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting, " Journal of Pain Research, vol. 7, pp. 579-588, 2014.
111. F. Sala A. Ciapetti, M. Carotti, S. Gasparini, and M. Gutierrez, "Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world, " BioMed Research International, vol. 2014, Article ID 528105, 12 pages, 2014.
112. C. D. Lorish, N. Abraham, J. S. Austin, L. A. Bradley, and G. S. Alarcón, "A comparison of the full and short versions of the arthritis impact measurement scales, " Arthritis Care & Research, vol. 4, no. 4, pp. 168-173, 1991.
113. R. F. Meenan, J. H. Mason, J. J. Anderson, A. A. Guccione, and L. E. Kazis, "AIMS2.)e content and properties of a revised and expanded arthritis impact measurement scales health status questionnaire, " Arthritis and Rheumatism, vol. 35, no. 1, pp. 1-10, 1992.
114. J. E. Ware and C. D. Sherbourne, ")e MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection, " Medical Care, vol. 30, no. 6, pp. 473-483, 1992.
115. J. Brazier, N. Jones, and P. Kind, "Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire, " Quality of Life Research, vol. 2, no. 3, pp. 169-180, 1993.
116. F. Sala M. Carotti, and W. Grassi, "Health-related quality of life in patients with hip or knee osteoarthritis: comparison of generic and disease-speci: c instruments, " Clinical Rheumatology, vol. 24, no. 1, pp. 29-37, 2005.
117. N. Bellamy, C. Wilson, and J. Hendrikz, "Population-based normative values for the Western Ontario and McMaster (WOMAC) osteoarthritis index: part I, " Seminars in Arthritis and Rheumatism, vol. 41, no. 2, pp. 139-148, 2011.
118. E. M. Roos, H. P. Roos, L. S. Lohmander, C. Ekdahl, and B. D. Beynnon, "Knee injury and osteoarthritis outcome score (KOOS)-development of a self-administered outcome measure, " Journal of Orthopaedic and Sports Physical 5erapy, vol. 28, no. 2, pp. 88-96, 1998.
119. A. K. Nilsdotter, L. S. Lohmander, M. Klassbo, and E. M. Roos, "Hip disability and osteoarthritis outcome score (HOOS)-validity and responsiveness in total hip replacement, " BMC Musculoskeletal Disorders, vol. 4, p. 10, 2003.
120. I. K. Y. Lo, S. Gri(n, and A. Kirkley, ")e development of a disease-speci: c quality of life measurement tool for osteoarthritis of the shoulder: the Western Ontario Osteoarthritis of the shoulder (WOOS) index, " Osteoarthritis and Cartilage, vol. 9, no. 8, pp. 771-778, 2001.
121. R. Padua, L. Padua, E. Ceccarelli et al., "Italian version of the disability of the arm, shoulder and hand (DASH) questionnaire. Cross-cultural adaptation and validation, " Journal of Hand Surgery, vol. 28, no. 2, pp. 179-186, 2003.
122. R. M. Bennett, R. Friend, K. D. Jones, R. Ward, B. K. Han, and R. L. Ross, ")e revised: bromyalgia impact questionnaire (FIQR): validation and psychometric properties, " Arthritis Research & 5erapy, vol. 11, no. 4, p. R120, 2009.
123. M. Di Carlo, A. Becciolini, V. Lato, C. Crotti, E. G. Favalli, and F. Sala ")e 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting, " Journal of Rheumatology, vol. 44, no. 3, pp. 279-285, 2017.
124. A. Doria, S. Rinaldi, M. Ermani et al., "Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants, " Rheumatology, vol. 43, no. 12, pp. 1580-1586, 2004.
125. Food and Drug Administration, Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims, Food and Drug Administration, March 2017, http://www. fda. gov/downloads/Drugs/Guidances/UCM193282. pdf.
126. G. Demiris, L. B. Afrin, S. Speedie et al., "Patient-centered applications: use of information technology to promote disease management and wellness. A white paper by the AMIA knowledge in motion working group, " Journal of the American Medical Informatics Association, vol. 15, no. 1, pp. 8-13, 2008.
127. R. Roine, A. Ohinmaa, and D. Hailey, "Assessing telemedicine: a systematic review of the literature, " Canadian Medical Association Journal, vol. 165, no. 6, pp. 765-771, 2001.
128. A. Ranzolin, J. C. T. Brenol, M. Bredemeier et al., "Association of concomitant: bromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis, " Arthritis and Rheumatism, vol. 61, no. 6, pp. 794-800, 2009.
129. L. C. Pollard, G. H. Kingsley, E. H. Choy, and D. L. Scott, "Fibromyalgic rheumatoid arthritis and disease assessment, " Rheumatology, vol. 49, no. 5, pp. 924-948, 2010.
130. E. Ton, M. F. Bakker, S. M. Verstappen et al., "Look beyond the disease activity score of 28 joints (DAS28): tender points in2uence the DAS28 in patients with rheumatoid arthritis, " Journal of Rheumatology, vol. 39, no. 1, pp. 22-27, 2012.
131. F. Wolfe, H. A. Smythe, M. B. Yunus et al., ")e American college of rheumatology 1990 criteria for the classi: cation of: bromyalgia. Report of the multicenter criteria committee, " Arthritis and Rheumatism, vol. 33, no. 2, pp. 160-172, 1990.
132. S. L. Whittle, A. N. Colebatch, R. Buchbinder et al., "Multinational evidence-based recommendations for pain management by pharmacotherapy in in2ammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e initiative, " Rheumatology, vol. 51, no. 8, pp. 1416-1425, 2012.
133. S. L. Whittle, B. L. Richards, E. Husni, and R. Buchbinder, "Opioid therapy for treating rheumatoid arthritis pain, " Cochrane Database of Systematic Reviews, vol. 11, Article ID CD003113, 2011.
134. L. J. Croord, "Adverse eects of chronic opioid therapy for chronic musculoskeletal pain, " Nature Reviews Rheumatology, vol. 6, no. 4, pp. 191-197, 2010.
135. B. L. Richards, S. L. Whittle, and R. Buchbinder, "Neuromodulators for pain management in rheumatoid arthritis, " Cochrane Database of Systematic Reviews, vol. 1, Article ID CD008921, 2012.
136. L. M. Arnold, D. L. Goldenberg, S. B. Stanford et al., "Gabapentin in the treatment of: bromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial, " Arthritis and Rheumatism, vol. 56, no. 4, pp. 1336-1344, 2007.
137. L. J. Croord, P. J. Mease, S. L. Simpson et al., "Fibromyalgia relapse evaluation and e(cacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebocontrolled trial with pregabalin, " Pain, vol. 136, no. 3, pp. 419-431, 2008.
138. P. J. Mease, I. J. Russell, L. M. Arnold et al., "A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with: bromyalgia, " Journal of Rheumatology, vol. 35, no. 3, pp. 502-514, 2008.
139. B. L. Richards, S. L. Whittle, and R. Buchbinder, "Antidepressants for pain management in rheumatoid arthritis, " Cochrane Database of Systematic Reviews, vol. 11, Article ID CD008920, 2011.
140. S. Ramiro, H. Radner, D. van der Heijde et al., "Combination therapy for pain management in in2ammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis), " Cochrane Database of Systematic Reviews, vol. 10, Article ID CD008886, 2011.
141. J. L. Marks, A. N. Colebatch, R. Buchbinder, and C. J. Edwards, "Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity, " Cochrane Database of Systematic Reviews, vol. 10, Article ID CD008952, 2011.
142. H. Radner, S. Ramiro, R. Buchbinder, R. B. Landewe, D. van der Heijde, and D. Aletaha, "Pain management for in-2ammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity, " Cochrane Database of Systematic Reviews, vol. 1, Article ID CD008951, 2012.
143. S. H. Roth and G. Boost, "An open trial of naproxen in rheumatoid arthritis patients with signi: cant esophageal, gastric, and duodenal lesions, " Journal of Clinical Pharmacology, vol. 15, no. 4, pp. 378-384, 1975.
144. L. Laine, S. P. Curtis, M. Langman et al., "Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-in2ammatory drug diclofenac, " Gastroenterology, vol. 135, no. 5, pp. 1517-1525, 2008.
145. F. K. Chan, A. Lanas, J. Scheiman, M. F. Berger, H. Nguyen, and J. L. Goldstein, "Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial, " 5e Lancet, vol. 376, no. 9736, pp. 173-179, 2010.
146. A. N. Colebatch, J. L. Marks, and C. J. Edwards, "Safety of non-steroidal anti-in2ammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for in2ammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis), " Cochrane Database of Systematic Reviews, vol. 11, Article ID CD008872, 2011.
147. National Collaborating Centre for Chronic Conditions (UK), Rheumatoid Arthritis: National Clinical Guidelines for Management and Treatment in Adults (NICE Clinical Guidelines, no. 79), Royal College of Physicians, London, UK, 2009, https://www. ncbi. nlm. nih. gov/books/NBK51812/.
148. Y. Tizabi, L. L. Hurley, Z. Qualls, and L. Akin: resoye, "Relevance of the anti-in2ammatory properties of curcumin in neurodegenerative diseases and depression, " Molecules, vol. 19, no. 12, pp. 20864-20879, 2014.
149. A. L. Lopresti, S. D. Hood, and P. D. Drummond, "Multiple antidepressant potential modes of action of curcumin: a review of its antiin2ammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects, " Journal of Psychopharmacology, vol. 26, no. 12, pp. 1512-1524, 2012.
150. Y. Yang, X. Wu, Z. Wei et al., "Oral curcumin has antiarthritic e(cacy through somatostatin generation via cAMP/PKA and Ca2+/CaMKII signaling pathways in the small intestine, " Pharmacological Research, vol. 95-96, pp. 71-81, 2015.
151. Y. Li, Y. Zhang, D. B. Liu, H. Y. Liu, W. G. Hou, and Y. S. Dong, "Curcumin attenuates diabetic neuropathic pain by downregulating TNF-in a rat model, " International Journal of Medical Sciences, vol. 10, no. 4, pp. 377-381, 2013.
152. F. T. Ji, J. J. Liang, L. Liu, M. H. Cao, and F. Li, "Curcumin exerts antinociceptive effects by inhibiting the activation of astrocytes in spinal dorsal horn and the intracellular extracellular signal-regulated kinase signaling pathway in rat model of chronic constriction injury, " Chinese Medical Journal, vol. 126, no. 6, pp. 1125-1131, 2013.
153. EMA/CHMP/425279/2013, Committee for Medicinal Products for Human Use (CHMP). Xeljanz Assessment Report, February 2017, http://www. ema. europa. eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002542/WC500154697. pdf.
154. G. G. Song, S. C. Bae, and Y. H. Lee, "E(cacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials, " Korean Journal of Internal Medicine, vol. 29, no. 5, pp. 656-663, 2014.
155. S. Ramiro, C. Gaujoux-Viala, J. L. Nam et al., "Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 73, no. 3, pp. 529-535, 2014.
156. X. Zhang, F. Liang, X. Yin et al., "Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis, " Clinical Rheumatology, vol. 33, no. 2, pp. 165-173, 2014.
157. E. Salgado, J. R. Maneiro, L. Carmona, and J. J. Gomez-Reino, "Safety pro: le of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis, " Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 871-882, 2014.
158. A. Berhan, "E(cacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies, " BMC Musculoskeletal Disorders, vol. 14, p. 332, 2013.
159. Y. He, A. Y. Wong, E. W. Chan et al., "E(cacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, " BMC Musculoskeletal Disorders, vol. 14, p. 298, 2013.
160. P. Kawalec, A. Mikrut, N. Wísniewska, and A. Pilc, ")e effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis, " Clinical Rheumatology, vol. 32, no. 10, pp. 1415-1424, 2013.
161. D. Vyas, K. M. O'Dell, J. L. Bandy, and E. G. Boyce, "Tofacitinib: the: rst Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis, " Annals of Pharmacotherapy, vol. 47, no. 11, pp. 1524-1531, 2013.
162. K. M. O'Dell and A. E. Rummel, "Tofacitinib: a novel oral Janus kinase inhibitor for rheumatoid arthritis, " Formulary, vol. 47, no. 10, pp. 350-358, 2012.
163. J. H. Coombs, B. J. Bloom, F. C. Breedveld et al., "Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial, " Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 413-416, 2010.
164. G. V. Wallenstein, K. S. Kanik, B. Wilkinson et al., "effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials, " Clinical and Experimental Rheumatology, vol. 34, no. 3, pp. 430-442, 2016.
165. E. G. Boyce, D. Vyas, E. L. Rogan, C. S. Valle-Oseguera, and K. M. O'Dell, "Impact of tofacitinib on patient outcomes in rheumatoid arthritis-review of clinical studies, " Patient Related Outcome Measures, vol. 7, pp. 1-12, 2016.
166. J. M. Kremer, B. J. Bloom, F. C. Breedveld et al., ")e safety and e(cacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebocontrolled phase IIa trial of three dosage levels of CP-690, 550 versus placebo, " Arthritis and Rheumatism, vol. 60, no. 7, pp. 1895-1905, 2009.
167. Y. Tanaka, M. Suzuki, H. Nakamura, S. Toyoizumi, S. H. Zwillich, and Tofacitinib Study Investigators, "Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate, " Arthritis Care & Research, vol. 63, no. 8, pp. 1150-1158, 2011.
168. R. Fleischmann, M. Cutolo, M. C. Genovese et al., "A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs, " Arthritis and Rheumatism, vol. 64, no. 3, pp. 617-629, 2012.
169. J. M. Kremer, S. Cohen, B. E. Wilkinson et al., "A phase IIb dose-ranging study of the ORAL JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone, " Arthritis and Rheumatism, vol. 64, no. 4, pp. 970-981, 2012.
170. D. van der Heijde, Y. Tanaka, R. Fleischmann et al., "Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study, " Arthritis and Rheumatism, vol. 65, no. 3, pp. 559-570, 2013.
171. E. B. Lee, R. Fleischmann, S. Hall et al., "Tofacitinib versus methotrexate in rheumatoid arthritis, " New England Journal of Medicine, vol. 370, no. 25, pp. 2377-2386, 2014.
172. J. S. Smolen, J. M. Kremer, C. L. Gaich et al., "Patientreported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON), " Annals of the Rheumatic Diseases, vol. 76, no. 4, pp. 694-700, 2016.
173. European Medicines Agency, "Summary of opinion for Olumiant, " February 2017, http://www. ema. europa. eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/004085/WC500218183. pdf.
174. M. Dougados, D. van der Heijde, Y. C. Chen et al., "Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study, " Annals of the Rheumatic Diseases, vol. 76, no. 1, pp. 88-95, 2017.